7 results about "Medication hypertension" patented technology

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

The disclosure features methods and compositions for the treatment of perivascular fibrosis and other hypertensive diseases and conditions, cardiovascular diseases, and chronic kidney disease.

The invention belongs to the technical field of Chinese medicine preparation, and specifically is a preparation method and application of a Chinese medicine preparation for treating hypertension complicating pregnancy. The method comprises the following steps: washing and drying Chinese medicinal materials in a prescribed amount, crushing them respectively, and mixing them uniformly to obtain a mixed powder A; soaking the remaining components in water according to the prescribed amount, decocting, filtering, and concentrating to obtain a Chinese medicine extract with a relative density; putting the obtained extract into a vacuum dryer for fluidized drying, and crushing them to obtain a mixed powder B after combined operation; and mixing the mixed powder A and the mixed powder B uniformly and sealing them for storage to obtain a finished product, so as to give full play to the efficacy of each medicine and avoid the loss of efficacy, so as to achieve a high release rate of the effective ingredients of the medicine, and significantly improve the stability and solubility of the medicine, thereby improving the therapeutic effect and cure rate of the medicine.

The present application relates to the field of medical technology, and specifically discloses a ginseng capsule and a preparation process thereof, comprising the following steps: step S1, preparing a chitosan-acetic acid solution; step S2, preparing a ginseng capsule; the drug ingredients are prepared from the following components by mass: 22-30 parts of ginseng, 15-25 parts of turmeric, 12-18 parts of astragalus, 5-10 parts of quercetin, 3-6 parts of cassia twig, and 8-14 parts of fish oil microcapsules; the formula of the present application has simple ingredients and a clear mechanism of action, the prepared ginseng capsule is easy to take orally, the drug has a high solubility, the patient compliance is good, no other treatment methods are required, and the therapeutic effect on hypertension is significant.

The present invention relates to novel sublingual compositions comprising an anti-fibrotic agent, as well as methods for their preparation. Wherein the composition comprising an anti- fibrotic agent such as pirfenidone or nintedanib and its analogs or pharmaceutically acceptable salts thereof. These novel sublingual compositions are intended for use in the treatment of fibrotic diseases, disorders, or conditions, such as idiopathic pulmonary fibrosis (IPF), and hypertensive diseases, disorders, or conditions such as pulmonary hypertension.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

The invention relates to medicine, and more particularly to cardiology, neurology and pulmonology, and can be used for examining the reaction of an organism to metered hypoxic hypercapnia, in particular for evaluating cerebral vessel reactivity and cerebral perfusion reserve, as well as for carrying out hypercapnic training aimed at increasing the resistance of an organism to adverse stress factors and preparing for surgical interventions involving a temporary restriction of the blood flow through the arteries supplying the brain, and for treating diseases, in particular cerebrovascular disorders, coronary perfusion disorders, hypertensive disease, respiratory insufficiency, and the like. Claimed is a device for inducing hypoxic hypercapnia containing cells that are configured in the form of helically twisted channels, wherein each channel forms one cell and is twisted along a helical path at an incline to the plane of the base of a cylinder in such a way that the inlet and the outlet of each channel are vertically diametrically opposed, and wherein a cylindrical housing is provided in the form of a module, the bottom part of which is formed in such a way as to be capable of interfacing with the top part of an identical module.